A. Core Lectures (Committee Reviewer)

Basic Psychopharmacology — 1.1–1.64
Mujeeb Shad, M.D. (Gemma Espejo, M.D.)

Anxiety Disorders: OCD — 2.1–2.38
Robert Howland, M.D. (Matej Markota, M.D.)

GAD, PTSD, Social Anxiety, Phobias, Panic Disorder — 3.1–3.40
Robert Howland, M.D. (Matej Markota, M.D.)

Depression — 4.1–4.72
Daniel G. Orr, M.D. (Marvin Leifer, M.D.)

Bipolar Disorder — 5.1–5.43
Po Wang, M.D. (Daniel G. Orr, M.D.)

Treatment of Schizophrenia — 6.1–6.62
Michael Jibson, M.D., Ph.D., Ira Glick, M.D. (Gemma Espejo, M.D.)

Personality Disorders — 7.1–7.81
Donald W. Black, M.D., Larry J. Siever, M.D., Mujeeb Shad, M.D., M.S.C.S. (Gemma Espejo, M.D.)

ADHD: Child / Adolescent / Adult — 8.1–8.72
Daniel G. Orr, M.D. (Marvin Leifer, M.D.)

Eating Disorders — 9.1–9.49
Kimberly Rosania, Ph.D., Jennifer Derenne, M.D., James Lock, M.D., Ph.D. (Lawrence Cohen, BCPP, Pharm.D.)

Substance Use Disorders: Overview — 10.1–10.67
Po Wang, M.D. (Andrew Olagunju, M.D.)

Insomnia & Sleep Disorders — 11.1–11.63
Rafael Pelayo, M.D., Lawrence Adler, M.D. (Zachary David Zuschlag, D.O.)

Women’s Wellness: Pregnancy & Breastfeeding — 12.1–12.40
Katherine E. Williams, M.D. (Daniel G. Orr, M.D.)

Basic Child & Adolescent Psychopharmacology — 13.1–13.25
Glen R. Elliott, Ph.D., M.D. (Mujeeb Shad, M.D.)

Geriatric Psychopharmacology — 14.1–14.30
Lawrence Adler, M.D., Linda Farho, Pharm.D. (Lawrence Cohen, BCPP, Pharm.D.)

Managing Neurocognitive Behavioral Symptoms in Major Neurocognitive Disorders — 15.1–15.50
James Ellison, M.D. (Lawrence Adler, M.D.)

Evaluating & Managing Side Effects of Psychiatric Medications — 16.1–16.42
Joseph F. Goldberg, M.D., Robert H. Howland, M.D. (Daniel G. Orr, M.D.)

Psychopharmacology Warnings & Management — 17.1–17.63
Daniel G. Orr, M.D. (Zachary David Zuschlag, D.O.)

B. Optional Lectures

Psychogenomics — 18.1–18.39
Daniel G. Orr, M.D. (Mujeeb Shad, M.D.)

The Art of Psychopharmacology — 19.1–19.22
Ira D. Glick, M.D., Richard Balon, M.D. (Marvin Leifer, M.D.)

Optional Course on Substance Abuse

Originally developed by Professor Charles P. O’Brien (University of Pennsylvania Medical School), this course addresses the opioid epidemic and responsible prescribing practices.
Topics include risks/benefits of opioids, non-opioid pain management, and addiction medications such as methadone, buprenorphine (Suboxone), naltrexone (Vivitrol), and naloxone (Narcan).

Summary Lectures

Psychopharmacology of Addiction — 20.1–20.71
Charles P. O’Brien, M.D., Ph.D., Mujeeb Shad, M.D. (Andrew Olagunju, M.D.)

Neurobiology of Addictions: Parts I & II — 21a.1–21a.58 & 21b.1–21b.61
Charles P. O’Brien, M.D., Ph.D., Mujeeb Shad, M.D. (Lawrence Adler, M.D.)

Full Course Lectures

Addiction: A Disease of the Brain — 22.1–22.50
Charles P. O’Brien, M.D., Ph.D. (Andrew Olagunju, M.D.)

Substance Abuse: The Nation’s #1 Health Problem — 23.1–23.31
James Cornish, M.D. (Matthew Macaluso, D.O.)

Cannabis — 24.1–24.46
Charles P. O’Brien, M.D., Ph.D., John T. Pichot, M.D. (Lawrence Cohen, BCPP, Pharm.D.)

Hallucinogens — 25.1–25.65
Benoit Dubé, M.D. (Robert H. Howland, M.D.)

Prescription Drug Abuse — 26.1–26.58
Kyle M. Kampman, M.D. (Justin Faden, D.O.)

Psychiatric Disorders & Psychotherapy of Substance Abuse — 27.1–27.52
Robert M. Weinrieb, M.D. (Saeed Ahmed, M.D.)

Medical Complications of Substance Abuse — 28.1–28.106
Phil Green, M.D., Vishal Madaan, M.D. (Andrew Fukuda, Ph.D.)

Genetics of Substance Abuse & Neuropharmacology of Opiates — 29.1–29.58
Wade Berrettini, M.D. (Matthew Macaluso, D.O.)

Genetics of Addiction — 30.1–30.51
Wade Berrettini, M.D. (Matthew Macaluso, D.O.)

Neurobiology of Addiction — 31.1–31.41
Charles P. O’Brien, M.D., Ph.D. (Edgar Hernandez, M.D.)

Cocaine & Stimulants — 32.1–32.43
Kyle M. Kampman, M.D. (Mark Mattioli, M.D.)

Nicotine Dependence — 33.1–33.46
Henry R. Kranzler, M.D. (Thomas Raedler, M.D.)

Alcohol Dependence — 34.1–34.41
Henry R. Kranzler, M.D. (Tiffany Schwasinger-Schmidt, M.D., Ph.D., FACP)

Back